恶性腹膜细胞学与I期非子宫内膜样子宫内膜癌死亡风险增加相关
回顾性观察队列研究分析2010-2016年SEER数据库中4506例I期非子宫内膜样子宫内膜癌患者,其中401例(8.9%)恶性腹膜细胞学阳性。倾向评分加权模型显示恶性腹膜细胞学与全因死亡风险近两倍增加相关(5年生存率63.4% vs 80.2%,HR 2.18,95%CI 1.78-2.66)。结论提示恶性腹膜细胞学是I期非子宫内膜样子宫内膜癌生存期缩短的预后因素。
要点
- I期非子宫内膜样子宫内膜癌中恶性腹膜细胞学阳性率为8.9%(401/4506)。
- 恶性腹膜细胞学与全因死亡风险增加相关(HR 2.18,95%CI 1.78-2.66)。
- 透明细胞癌、T1a期、年龄>78岁和浆液性肿瘤中5年生存率差异较大。
核心结论
- 研究提示恶性腹膜细胞学是I期非子宫内膜样子宫内膜癌生存期缩短的预后因素。
研究设计与样本
- 回顾性观察队列研究,分析美国国立癌症研究所监测、流行病学和最终结果(SEER)项目2010至2016年数据。
- 纳入4506例I期浆液性、透明细胞、癌肉瘤、未分化及混合性子宫内膜癌且子宫切除术时腹膜细胞学结果已知的患者。
- 采用倾向评分逆概率治疗加权平衡协变量,按腹膜细胞学结果评估生存结局。
主要发现
- 401例(8.9%)报告恶性腹膜细胞学。
- 多因素分析中,年龄较大、浆液性组织学和大肿瘤与恶性腹膜细胞学可能性增加相关(均P < 0.05)。
- 倾向评分加权模型中,恶性腹膜细胞学与阴性腹膜细胞学相比,全因死亡风险增加近两倍(5年率63.4% vs 80.2%,HR 2.18,95%CI 1.78-2.66)。
- 敏感性分析中,恶性腹膜细胞学与总生存期降低相关见于老年和年轻年龄组、浆液性、透明细胞、癌肉瘤和混合性组织学组、T1a期病变以及分期和未分期病例,但T1b期病变不相关。
- 恶性与阴性腹膜细胞学组5年总生存率差异在透明细胞组织学(24.0%)、T1a期病变(19.4%)、年龄>78岁(18.2%)和浆液性肿瘤(17.6%)中尤其大。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the survival of women with stage I non-endometrioid endometrial cancer with malignant peritoneal cytology. METHODS: A retrospective observational cohort study was conducted to examine the National Cancer Institute's Surveillance, Epidemiology, and End Results Program from 2010 to 2016. Women with stage I serous, clear cell, carcinosarcoma, undifferentiated, and mixed endometrial cancer with known peritoneal cytology results at hysterectomy were examined (N = 4506). Propensity score inverse probability of treatment weighting was used to balance the measured covariates, and survival outcomes were assessed according to peritoneal cytology results. RESULTS: Malignant peritoneal cytology was reported in 401 (8.9%) women. In multivariable analysis, older age, serous histology, and large tumors were associated with an increased likelihood of malignant peritoneal cytology (all, P < 0.05). In a propensity score weighted model, malignant peritoneal cytology was associated with a nearly two-fold increase in all-cause mortality risk compared to negative peritoneal cytology (5-year rates, 63.4% versus 80.2%, hazard ratio 2.18, 95% confidence interval 1.78-2.66). In sensitivity analyses, malignant peritoneal cytology was associated with decreased overall survival in old and young age groups, serous, clear cell, carcinosarcoma, and mixed histology groups, stage T1a disease, and staged and unstaged cases, but not for stage T1b disease. Difference in 5-year overall survival rates between the malignant and negative peritoneal cytology groups was particularly large among those with clear cell histology (24.0%), stage T1a disease (19.4%), aged >78 years (18.2%), and serous tumors (17.6%). CONCLUSION: Malignant peritoneal cytology can be prevalent in stage I non-endometrioid endometrial cancer. Our study suggests that malignant peritoneal cytology is a prognostic factor for decreased survival in stage I non-endometrioid endometrial cancer.
引用
- Matsuo K, Nusbaum DJ, Matsuzaki S, et al. Malignant peritoneal cytology and increased mortality risk in stage I non-endometrioid endometrial cancer. Gynecol Oncol. 2020. PMID: 32690393. doi:10.1016/j.ygyno.2020.07.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。